{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "b95d088a1d0e6d0cc8b15e2a303ee604",
    "title": "Jefferies",
    "source_uri": "2025-08-29/FY25 - Wouldnt It Be NiceFY25 - Wouldnt It Be Nice_2025-08-29",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-27T00:40:46.068591",
      "extracted_at": "2025-10-27T00:40:46.068598"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 13,
        "successful_pages": 13,
        "date": "2025-08-29",
        "publication": "2025-08-29",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 2,
          "removed_paragraphs": 7,
          "reduction_ratio": 0.12217676332663407
        },
        "input_relative_path": "2025-08-29"
      }
    }
  },
  "passages": [
    {
      "passage_id": "46c3746e8e220e3a",
      "text": "Australia | Biotechnology Clarity",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "5f9761b6216f6387",
      "text": "CU6 will be hoping for momentum from upcoming catalysts. These include the readout of the Co- PSMA trial. Should trials be successful, the CU6's potential radiodiagnostic is likely to be able to readily access a solid patient population. We update for CU6 FY25 financial results.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "709d603263e56c62",
      "text": "FY25 result. Compared to our forecasts, CU6 had higher R&D and employment expenses. Clarity recently completed a A\\$203m placement. Funds will be used for: 1) clinical development; 2) pipeline advancements; and 3) manufacturing expansion of 64Cu- SAR- BisPSMA.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "3c4ad9d4da0989ec",
      "text": "CU6's assets advancing. Clarity's SAR- bisPSMA is progressing through four clinical trials: one theranostic trial (SECuRE), two Phase 2 diagnostic trials (CLARIFY and AMPLIFY) and an Investigator- Initiated Trial (IIT, Co- PSMA). Clarity also shared positive topline data for the 64Cu- SARTATE and 64Cu- SAR- Bombesin products from its diagnostic Phase 2 trials, DISCO in NETs and SABRE in PSMA- negative biochemically recurrent (BCR) prostate cancer patients who are negative on standard- of- care imaging, respectively. Based on these results, Clarity is taking next steps for registration of 64Cu- SARTATE and 64Cu- SAR- Bombesin with the guidance of the US FDA. Clarity will continue to progress its Discovery Program, aiming to bring key assets such as 64Cu- SAR- bisFAP and 64/67Cu- SAR- trastuzumab to the clinic.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "7c2dbba104393e79",
      "text": "Analysis of CU6's Co- PSMA trial suggests at least c15.6K US pt market, should the trial be successful. For the Co- PSMA trial, we note that eligible patients were required to have had radical prostatectomy with no salvage therapy and a prostate- specific antigen (PSA) between 0.2 and \\(0.75 \\text{ng / mL}\\) . Our analysis suggests that should the Co- PSMA trial be successful, then the population that would benefit clinically from CU6's BisPSMA diagnostic would be c15.6K patients per annum in the US. That said, CU6's product could be used much more widely than this population. We will update our views in line with the clinical evidence generated for the use of the CU6 radiodiagnostic product being tested in the CLARIFY and AMPLIFY trials.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "1e832c8d311e449a",
      "text": "Changes to forecasts. We have: 1) Updated cost lines for FY26E in line with FY25; and 2) updated for net interest for FY26E+. We make no changes to our CU6 revenue forecasts.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "7feb9cdc314d1c93",
      "text": "PT A\\$5.00 (unchanged). We use the NPV of CU6's late- stage pipeline as our price target.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "1d39aff4c83f10a3",
      "text": "FY (Jun)2024A2025A2026E2027ERev. (MM)11.59.521.227.5EBITDA (MM)(37.4)(68.7)(76.5)(78.2)Net Profit(35.7)(64.1)(67.6)(69.7)EPS(0.11)(0.19)(0.19)(0.18)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "cb5c992f6fc1e433",
      "text": "Please see analyst certifications, important disclosure information, and information regarding the status of non-US analysts on pages 8 - 13 of this report. \\\\* Jefferies (Australia) Pty Ltd",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "08700e2e9fdb430e",
      "text": "RATINGBUYPRICEAUD3.18*PRICE TARGET | % TO PTAUD5.00 | +57%52W HIGH-LOWAUD8.98 - AUD1.43FLOAT (%) | ADV MM (USD)66.7% | 12.91MARKET CAPAUD1.1B | $700.9MTICKERCU6 AU",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "62fb100e7dad0107",
      "text": "\\\\*Prior trading day's closing price unless otherwise noted.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "2589de5b288c9cba",
      "text": "FY (Jun)CHANGE TO JEFEJEF vs CONS2026202720262027REV+22%+22%NANAEPS-19%-22%NANA",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "09343787394c6b29",
      "text": "Figure 1 - Clarity Pharma - risk-weighted valuation of portfolio",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "443a9517120569d7",
      "text": "Figure 2 - Clarity Pharma - revenue by product (ASm)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "5493b3ba1ef07ab9",
      "text": "Source: Jefferies estimates",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "3324f40245db10af",
      "text": "CU6 is not without risks, but there is the chance for meaningful upside should its products be approved. Obviously, CU6's major potential hurdle is further positive late- stage clinical trial results and then regulatory approval. That said, if successful, CU6 would likely gain a large market share in this relatively new field of medicine. We believe this is an attractive investment opportunity for investors with a higher risk appetite.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "f6c6d3e3fa19cf3d",
      "text": "Risk/Reward - 12 Month View",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "5e4000d1fba535e3",
      "text": "Base Case, AUD5, +57%",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "dd232087ca0c8dcf",
      "text": "Our base case price target uses our risk- weighted valuations for the near- term products in the CU6 pipeline. These are: 1) Diagnosis of neuroendocrine tumours; 2) Diagnosis of PSMA +ve prostate cancer; 3) Treatment of PSMA+ve prostate cancer and 4) Diagnosis of PSMA -ve prostate cancer.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "fd8a32c25db12a82",
      "text": "Upside Scenario, AUD16.48, +418%",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "5a5c2a174e0d5745",
      "text": "Our upside case price target is a non- risk- weighted valuation of CU6's base- case opportunities.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "a1300fe6802a732b",
      "text": "Downside Scenario, AUD0.03, - 99%",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "cd2edda1f3ba9a1a",
      "text": "Our downside case assumes all clinical trials fail. In this case, the stock would likely trade at its cash backing, which is our downside case.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "dee265a09a2467c8",
      "text": "Pricing is a major issue. Device and drug pricing has always been tied to several social considerations of ESG, such as customer relationships, demographic changes, and social awareness, and it has continually been among the main measures of reputation and regulatory risk.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "ca7f64426cb26f5f",
      "text": "1) No targets for reducing its emissions.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "2e51a2ad89d59775",
      "text": "2) Sustainability targets have not been set by the company.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "3f50825b78f7a3ce",
      "text": "1) How is CU6 expanding its ESG framework in line with its ongoing need for funds to continue with its R&D pipeline?",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "ffb64ee197037911",
      "text": "2) How is CU6 ensuring safe disposal of radiopharmaceuticals?",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "729e17dc566a7895",
      "text": "3) How is CU6 ensuring safety of clinical trial participants?",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "46341b2dea48b655",
      "text": "4) Sector Deep Dive Update: Australian Healthcare",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "eeb33f18770ac2b2",
      "text": "CU6's near- term product candidates use its technologies in the treatment/diagnosis of prostate cancer, as well as neuroendocrine tumours (NETs). Success in any of these clinical trials would lead to a positive re- rating of CU6's share price, in our view.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "7e62d9fd80117aa9",
      "text": "(Note: To commemorate the recent passing of founder Brian Wilson, we will be using Beach Boys' songs for our note titles in this reporting season.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "07406a14cd21360c",
      "text": "Figure 3 - Clarity Pharma - Expanded Summary Table (ASm)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "cae182895aacbf17",
      "text": "Year-end 30 June (ASm)FY24AFY25AFY26EFY27EFY28ERevenue129212879EBITDA(37)(69)(77)(78)(8)EBIT(38)(69)(77)(79)(9)Normalised NPAT(36)(64)(68)(70)(5)JEF NPAT/consensus (%)nananananaFully diluted norm EPS(0.11)(0.19)(0.19)(0.18)(0.01)EPS growth on pcp (%)32.165.6(1.8)(3.4)(93.3)EV/EBITDA (x) (JEF)(25.2)(14.2)(13.0)(13.6)(138.8)EV/EBIT (x) (JEF)(25.1)(14.1)(12.9)(13.5)(115.6)FD normalised P/E (x) (JEF)(27.8)(15.9)(17.4)(16.9)(252.8)Dividend yield (%)0.00.00.00.00.00ROE(24.4)(71.0)(29.9)(44.6)(3.1)Net debt/equity (%)net cashnet cashnet cashnet cashnet cash",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "3fd0990394b91f5f",
      "text": "Source: Company data, Jefferies estimates, IRESS",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "97483b567917d2f2",
      "text": "Upcoming catalysts for CU6 include the readout of the Co- PSMA trial. Should this trial be successful, the CU6's potential radiodiagnostic is likely to be able to readily access a solid patient population. We update for CU6 FY25 financial results.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "108065c2e65e2e57",
      "text": "We have: 1) Updated cost lines for FY26E in line with FY25; and 2) updated for net interest for FY26E +. We make no changes to our CU6 revenue forecasts.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "46a46e14417c5ba8",
      "text": "Figure 4 - Clarity Pharma - changes to forecasts (ASm)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "37438c7359a9f488",
      "text": "FY25AFY26EFY27EFY28EPrevRevDiff (%)PrevRevDiff (%)PrevRevDiff (% )PrevRevDiff (%)Sales revenue (ASm)0.00.00.00.00.000.00.00.048.448.40.0EBITDA (ASm)(46.1)(68.7)(60.4)(76.5)(62.0)(78.2)2.6(7.7)EBIT (ASm)(46.3)(68.9)(60.6)(76.9)(62.3)(78.7)1.6(9.2)NPAT (ASm)(44.0)(64.1)(56.8)(67.6)(57.4)(69.7)3.1(4.7)EPS (c)(13.0)(19.0)(15.6)(18.6)(14.8)(18.0)0.8(1.2)DPS (c)0.00.00.00.00.000.00.00.0Net op cashflow (ASm)(43.6)(54.8)(56.3)(66.5)(56.6)(68.2)4.8(1.9)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "700e9abade226ebf",
      "text": "Source: Company data, Jefferies estimates",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "88d44fdddc7a0c38",
      "text": "Clarity's SAR- bisPSMA is progressing through four clinical trials: one nanostic trial (SECuRE), two Phase 2 diagnostic trials (CLARIFY and AMPLIFY) and an Investigator- Initiated Trial (IIT, Co- PSMA).",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "4c0dd9b9dbe5ee59",
      "text": "Clarity also shared positive topline data for the 64Cu- SARTATE and 64Cu- SAR- Bombesin products from its diagnostic Phase 2 trials, DISCO in NETS and SABRE in PSMA- negative biochemically recurrent (BCR) prostate cancer patients who are negative on standard- of- care imaging, respectively. Based on these results, Clarity is taking next steps for registration of 64Cu- SARTATE and 64Cu- SAR- Bombesin with the guidance of the US FDA.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "e1ad6e0dd34494a4",
      "text": "Clarity will continue to progress its Discovery Program, aiming to bring key assets such as 64Cu- SAR- bisFAP and 64/67Cu- SAR- trastuzumab to the clinic.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "dedd369cc6a7613c",
      "text": "For the Co- PSMA trial, we note that eligible patients were required to have had radical prostatectomy with no salvage therapy and a prostate- specific antigen (PSA) between 0.2 and 0.75 ng/mL.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "9ba559ca68691ca5",
      "text": "The most recent and comprehensive data (2016, we assume this grows by \\(2\\%\\) per annum since then) from the US Nationwide Inpatient Sample indicate that c68.5K men in the United States underwent a radical prostatectomy in CY24. The scientific literature suggests that Biochemical recurrence (BCR) occurs in \\(c20 - 40\\%\\) of men after radical prostatectomy. Again, the literature suggests that among men who experience BCR after radical prostatectomy, virtually none (JEF",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "66399b12390b25e2",
      "text": "assumes \\(5\\%\\) ) present with a PSA less than \\(0.2 \\mathrm{ng / mL}\\) . Among men who experience BCR after radical prostatectomy, \\(c25\\%\\) present with a PSA greater than \\(0.75 \\mathrm{ng / mL}\\) at the time of BCR.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "a5d20450474ec184",
      "text": "Hence, should the Co- PSMA trial be successful, then the population that would benefit clinically from CU6's BisPSMA diagnostic would be \\(c15.6K\\) patients per annum in the US. We now assume full year volumes of this magnitude upon market entry for CU6's BisPSMA diagnostic. That said, CU6's product could be used much more widely than this population. We will update our views in line with the clinical evidence generated for the use of the CU6 radiodiagnostic product being tested in the CLARIFY and AMPLIFY trials.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "4453e23e5024cc8a",
      "text": "Figure 5 - Clarity Pharma - Co-PSMA trial potential US patients per annum (000)",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "f760de8bee199f22",
      "text": "Co-PSMA trial potential US patients per annum (000)CY24E: No. of men in the US who had radical prostatectomy68.5BCR occurs in c20-40% of men after radical prostatectomy, assume 30%20.5CY24E: With BCR postradical prostatectomy, c70% present with a PSA &amp;lt;0.75 ng/mL14.4Assume 2% growth in market CY24 to CY28E, no. of CY28E scans based on above15.6",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "4b06cb66f2842e1f",
      "text": "Source: Company data, PubMed",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "2753fd490fe64a04",
      "text": "Should its products be successful, Clarity essentially will offer two types of products:",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "62fb455b5cc65c09",
      "text": "- Imaging of cancer: Clarity will provide the centrally-manufactured product for a hospital to use. This centrally-manufactured product includes: 1) CU6's cancer-finding molecule, mixed with 2) radioactive isotope (64Cu, from a cyclotron for diagnosis of cancer) to then administer the product to cancer patients, so the cancer can be seen in a PET scan (which detects radiation). CU6 is using radioactive copper for diagnosis - 64Cu for its diagnostic products, which has a half-life of 12.7 hours.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "9e8e17f959533086",
      "text": "- Treatment of same cancer: Clarity will provide the centrally-manufactured product for a hospital to use. This centrally-manufactured product includes: 1) CU6's cancer-finding molecule, mixed with 2) radioactive isotopes (67Cu, from an electron accelerator for the treatment of cancer) to then administer the product to cancer patients, so the cancer can be treated with internal radiation. CU6 is using radioactive copper for treatment - 67Cu for its therapeutic products, which has a half-life of 2.6 days.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "c14387a72e7a57f5",
      "text": "The benefits of theranostic nuclear oncology include that treatment is offered only to those individual cancer patients in whom tumour molecular uptake of the theranostic radionuclide pair is seen on pre- treatment diagnostic/staging PET/CT imaging of the targeted cancer. Similarly, subsequent cycles of treatment with theranostic agents are only administered after specific PET/CT verification of continuing tumour- avidity and monitoring of response in order to reliably predict efficacy and minimise toxicity.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "194e0417671fab03",
      "text": "CU6's products are predicated upon the radiolabelling of cancer type- specific biomarkers, which allow precise molecular imaging to reflect the unique molecular pathology of tumour cells. This strategy identifies individual patients who may then benefit from tumour molecular phenotype- targeted radionuclide therapy. CU6 forecast revenue by product is shown below.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "e389b3826931aeaf",
      "text": "Figure 6 - Clarity Pharma - revenue by product (ASm)",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "58885da9801fb0d3",
      "text": "Source: Jefferies estimates",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "edc600544d90fb1c",
      "text": "This is outlined below.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "96eed209c576c870",
      "text": "Figure 7 - Clarity Pharma - Income statement (A\\$m)",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "6365d24688e0c65f",
      "text": "Income Statement (A$m)1H24A2H24AFY24A1H25A2H25AFY25A1H25 on 1H24 (%)2H25 on 2H24 (%)FY25 on FY24 (%)Sales revenue0.00.00.00.00.000.0Other revenue5.46.111.54.74.89.5(13.5)(21.6)(17.8)COGS0.00.00.00.00.000.0Other expenses(23.1)(25.8)(48.9)(34.4)(43.8)(78.2)Operating EBITDA(17.7)(19.7)(37.4)(29.7)(39.0)(68.7)Depreciation &amp;amp; Amortisation(0.1)(0.1)(0.2)(0.1)(0.1)(0.1)Operating EBIT(17.7)(19.8)(37.6)(29.8)(39.1)(68.9)Other income0.00.00.00.00.000.0Net interest expense1.11.72.82.91.94.8161.712.771.8Pre-tax profit(17.1)(18.3)(35.4)(23.5)(40.2)(63.7)Tax(0.1)(0.2)(0.3)(0.0)(0.4)(0.4)Profit after tax(17.2)(18.5)(35.7)(23.6)(40.5)(64.1)Minorities0.00.00.00.00.000.0Normalised NPAT(17.2)(18.5)(35.7)(23.6)(40.5)(64.1)Non-recurring items0.0(6.6)(6.6)0.0(0.2)(0.2)Reported profit(17.2)(25.1)(42.3)(23.6)(40.7)(64.3)Per shareNormalised EPS (cps)(6.6)(5.9)(11.5)(7.4)(12.0)(19.0)DPS (cps)0.00.00.00.00.000.0Average shares (m)261.9311.4311.4317.2337.8337.821.18.58.5Ratio analysis (%)Diff (bp)Diff (bp)Diff (bp)EBITDA marginnananananananaEBIT marginnananananananaEffective tax ratenanananananana",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "03a57df2af3d9e32",
      "text": "Source: Jefferies estimates, company data",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "0a2ca9ce3a7f41e2",
      "text": "CU6's BisPSMA radiodiagnostic initial market size: based on the above analysis, we assume a CU6 BisPSMA radiodiagnostic initial market size of c15.6K patients per annum in the US on a full- year basis Market entry for CU6's BisPSMA radiodiagnostic: we assume US reimbursement approval for CU6 BisPSMA radiodiagnostic at start 2HFY28E. Market entry for CU6's CU6 SAR Bombesin radiodiagnostic: we assume US reimbursement approval for CU6 SAR Bombesin radiodiagnostic in FY30E. Market entry for CU6's 67Cu SAR BisPSMA radiotherapeutic: we assume US reimbursement approval for CU6's 67Cu SAR BisPSMA radiotherapeutic in FY31E.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "b566f31210c9ade0",
      "text": "We make no changes to our CU6 revenue forecasts. We have made the following changes to our forecasts:",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "e365a412c7535274",
      "text": "Costs: we have updated cost lines for FY26E in line with FY25 Net interest expense: This has been recalculated in line with period- end balances.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "d1e8bf0fceb02e7c",
      "text": "According to data from Tufts University, the probability of success of clinical trials depends upon the stage of the clinical trial. This is shown in the figure below.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "be4ad62151dbfeb2",
      "text": "Figure 8 - Probability of drug at clinical phase stage ultimately getting to market (TuftsDiMasi data)",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "753a34a5d4cea568",
      "text": "PhaseProbability of success of moving to the next phase (%)Probability of drug getting onto market from a particular phase (%)Phase 162.513.4Phase 235.021.4Phase 368.061.2Filing90.090.0",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "9ccfa3b84e7f8707",
      "text": "In terms of valuation, there are four major potential commercial opportunities for CU6: 1) neuroendocrine tumour Imaging; 2) PSMA- positive Prostate Cancer Imaging; 3) PSMA- positive Prostate Cancer Treatment; and 4) PSMA- negative Prostate Cancer Imaging. Our risk- weighted calculations of the near- term valuations in the CU6 pipeline are shown below. We use these valuations of the CU6 pipeline to calculate our price target.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "0965a9b243b1d749",
      "text": "Figure 9 - Clarity Pharma - valuation methodology",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "2a6226cb399cd224",
      "text": "Valuation of CU6 R&amp;amp;D portfolioRisk-weighted valuation (A$ per share)Risk Weighting (in line with clinical trial stage) (%)Total opportunity size (A$ per share)Opp. As % of risk-weighted valuation64Cu SAR-bisPSMA (BCR)2.1061.23.4342%67Cu SAR-bisPSMA2.6821.412.5054%NeuroEndo Ca Diagnostic0.1061.20.162%PSMA neg. Prost. Ca Diagnostic0.0821.40.392%Total valuation (A$, rounded)5.00",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "c923eb415bf2f735",
      "text": "Source: Jefferies estimates",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "4866f2f9cc106be8",
      "text": "Figure 10 - Clarity - Financial Summary (US\\\\$m)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "6abcb7ad71a034cc",
      "text": "CUE: Year-end 30 JuneFY24AFY25AFY26EFY27EFY28E",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "e041c9b439787080",
      "text": "ClarityClarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product is SAR- BisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express specific membrane antigen. It is developing Sartate, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. Finally, the company is also developing SAR- Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "02bc496491ffcd65",
      "text": "In terms of valuation, there are four major potential commercial opportunities for CU6: 1) neuroendocrine tumour Imaging; 2) PSMA- positive Prostate Cancer Imaging; 3) PSMA- positive Prostate Cancer Treatment; and 4) PSMA- negative Prostate Cancer Imaging. Our risk- weighted calculations of the near- term valuations in the CU6 pipeline are shown below. We use these valuations of the CU6 pipeline to calculate our price target.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "847cc63c4db96dca",
      "text": "In terms of upside risks, CU6's product candidates use its technologies in the treatment/diagnosis of: 1) Prostate Cancer; and 2) Neuroendocrine Tumours. Success in any of these clinical trials would lead to a positive re- rating of CU6's share price, in our view. In terms of downside risks, there is still uncertainty around CU6's viability in most of its prospective markets. Pre- clinical trials, although positive, give no firm indication of a product's true viability, and future market conditions are unknown. To date, all preclinical and clinical trials have shown indications for the product's viability. In terms of downside risks, CU6's major potential stumbling block is further positive late- stage clinical trial results and then regulatory approval.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "b1dbb884625aa044",
      "text": "(Article 3(1)e and Article 7 of MAR) Recommendation Published Recommendation Distributed",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "b6df29504ae3d00e",
      "text": "August 29, 2025 0:53 A.M. August 29, 2025 0:53 A.M.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "38b2510df4aaace3",
      "text": "Buy - Describes securities that we expect to provide a total return (price appreciation plus yield) of \\(15\\%\\) or more within a 12- month period. Hold - Describes securities that we expect to provide a total return (price appreciation plus yield) of plus \\(15\\%\\) or minus \\(10\\%\\) within a 12- month period. Underperform - Describes securities that we expect to provide a total return (price appreciation plus yield) of minus \\(10\\%\\) or less within a 12- month period. The expected total return (price appreciation plus yield) for Buy rated securities with an average security price consistently below \\(10\\) or more within a 12- month period as these companies are typically more volatile than the overall stock market. For Hold rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is plus or minus \\(20\\%\\) within a 12- month period. For Underperform rated",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "8d2e1b108e697f2b",
      "text": "securities with an average security price consistently below \\(10, the expected total return (price appreciation plus yield) is minus 20% or less within a 12- month period.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "084ec319987f2cc3",
      "text": "NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Jefferies policies.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "da7b65023085f650",
      "text": "CS - Coverage Suspended. Jefferies has suspended coverage of this company.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "ad367a8245a2bed0",
      "text": "NC - Not covered. Jefferies does not cover this company.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "cde2a2670315757f",
      "text": "Restricted - Describes issuers where, in conjunction with Jefferies engagement in certain transactions, company policy or applicable securities regulations prohibit certain types of communications, including investment recommendations.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "8aefd330e8a9897f",
      "text": "Monitor - Describes securities whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "782ab4a473c4f922",
      "text": "Jefferies methodology for assigning ratings may include the following: market capitalization, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "0d5436767ee8fcba",
      "text": "Jefferies Franchise PicksJefferies Franchise Picks include stock selections from among the best stock ideas from our equity analysts over a 12 month period. Stock selection is based on fundamental analysis and may take into account other factors such as analyst conviction, differentiated analysis, a favorable risk/reward ratio and investment themes that Jefferies analysts are recommending. Jefferies Franchise Picks will include only Buy rated stocks and the number can vary depending on analyst recommendations for inclusion. Stocks will be added as new opportunities arise and removed when the reason for inclusion changes, the stock has met its desired return, if it is no longer rated Buy and/or if it triggers a stop loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not sector based, but we may note where we believe a Pick falls within an investment style such as growth or value.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "4fdace2ba4c6b0a0",
      "text": "- Clarity Pharmaceuticals Ltd (CU6 AU: AUD3.18, BUY)",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "9d976aeeb89113bc",
      "text": "Notes: Each box in the Rating and Price Target History chart above represents actions over the past three years in which an analyst initiated on a company, made a change to a rating or price target of a company or discontinued coverage of a company. Legend:",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "4146d8fe05933c44",
      "text": "I: Initiating Coverage D: Dropped Coverage B: Buy H: Hold UP: Underperform",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "0993617c6cfaf34b",
      "text": "Distribution of Ratings",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "66e5ed54b94ed48a",
      "text": "CountPercentCountPercentCountPercentBUY211160.63%37017.53%1185.59%HOLD121334.84%1058.66%221.81%UNDERPERFORM1584.54%31.90%31.90%",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "0d94ebb26d2161d6",
      "text": "Jefries does busines and seeks to do business with companies covered in its research reports, and expects to receive or intends to seek compensation for investment banking services among other activities from such companies. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Jefferies Equity Research refers to research reports produced by analysts employed by one of the following Jefferies Financial Group Inc. (Jefferies) companies:",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "a0f50a3ed52a72ad",
      "text": "United States: Jefferies LLC which is an SEC registered broker- dealer and a member of FINRA (and distributed by Jefferies Research Services, LLC, an SEC registered Investment Adviser, to clients paying separately for such research).",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "b9d09901a17c72a8",
      "text": "Canada: Jefferies Securities Inc., which is an investment dealer registered in each of the thirteen Canadian jurisdictions and a dealer member of the Canadian Investment Regulatory Organization, including research reports produced jointly by Jefferies Securities Inc. and another Jefferies entity (and distributed by Jefferies Securities Inc.).",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "95181260685c6d45",
      "text": "Where Jefferies Securities Inc. distributes research reports produced by Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch or Jefferies India Private Limited, you are advised that each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited operates as a dealer in your jurisdiction under an exemption from the dealer registration requirements contained in National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations and, as such, each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited is not required to be and is not a registered dealer or adviser in your jurisdiction. You are advised that where Jefferies LLC or Jefferies International Limited prepared this research report, it was not prepared in accordance with Canadian disclosure requirements relating to research reports in Canada.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "adf3e7d5e4862440",
      "text": "United Kingdom: Jefferies International Limited, which is authorized and regulated by the Financial Conduct Authority, registered in England and Wales No. 1978621; registered office: 100 Bishopsgate, London EC2N 4JL; telephone +44 (0)20 7029 8000; facsimile +44 (0)20 7029 8010.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "14e2d9b61a15c376",
      "text": "Japan: Jefferies (Japan) Limited, Tokyo Branch, which is a securities company registered by the Financial Services Agency of Japan and is a member of the Japan Securities Dealers Association; located at Tokyo Midtown Hibiya 30F Hibiya Mitsui Tower, 1- 1- 2 Yurakucho, Chiyoda- ku, Tokyo 100- 0006; telephone +813 5251 6100; facsimile +813 5251 6101.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "bfe5ea0bd9d969c7",
      "text": "Australia: Jefferies (Australia) Pty Limited (ACN 623 059 898), which holds an Australian financial services license (AFSL 504712) and is located at Level 20, 60 Martin Place, Sydney NSW 2000; telephone +61 2 9364 2800.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "43dacde497489e2f",
      "text": "Dubai: Jefferies International Limited, Dubai branch, which is licensed by the Dubai Financial Services Authority (DFSA Reference Number F007325); registered office Unit L31- 06, L31- 07, Level 31, ICD Brookfield Pace, DIFC, PO Box 121208, Dubai, UAE.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "97e107dc40f3dc0f",
      "text": "This report was prepared by personnel who are associated with Jefferies (Jefferies Securities Inc., Jefferies International Limited, Jefferies GmbH, Jefferies Hong Kong Limited, Jefferies Singapore Limited, Jefferies (Japan) Limited, Tokyo Branch, Jefferies India Private Limited), and Jefferies (Australia) Pty Ltd; or by personnel who are associated with both Jefferies LLC and Jefferies Research Services LLC (\"JRS\"). Jefferies LLC is a US registered broker- dealer and is affiliated with JRS, which is a US registered investment adviser. JRS does not create tailored or personalized research and all research provided by JRS is impersonal. If you are paying separately for this research, it is being provided to you by JRS. Otherwise, it is being provided by Jefferies LLC. Jefferies LLC, JRS, and their affiliates are collectively referred to below as \"Jefferies\". Jefferies may seek to do business with companies covered in this research report. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only one of many factors in making their investment decisions. Specific conflict of interest and other disclosures that are required by FINRA, the Canadian Investment Regulatory Organization and other rules are set forth in this disclosure section.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "b32dd60076018659",
      "text": "If you are receiving this report from a non- US Jefferies entity, please note the following: Unless prohibited by the provisions of Regulation S of the U.S. Securities Act of 1933, as amended, this material is distributed in the United States by Jefferies LLC, which accepts responsibility for its contents in accordance with the provisions of Rule 15a- 6 under the US Securities Exchange Act of 1934, as amended. Transactions by or on behalf of any US person may only be effected through Jefferies LLC. In the United Kingdom and European Economic Area this report is issued and/or approved for distribution by Jefferies International Limited (\"JIL\") and/or Jefferies GmbH and is intended for use only by persons who have, or have been assessed as having, suitable professional experience and expertise, or by persons to whom it can be otherwise lawfully distributed. Jefferies LLC, JIL, Jefferies GmbH and their affiliates, may make a market or provide liquidity in the financial instruments referred to in this report; and where they do make a market, such activity is disclosed specifically in this report under \"company specific disclosures\".",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "558aab40ec80049b",
      "text": "For Canadian investors, this material is intended for use only by professional or institutional investors. None of the investments or investment services mentioned or described herein is available to other persons or to anyone in Canada who is not a \"permitted client\" as defined by National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations, as applicable. This research report is a general discussion of the merits and",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "7e7803949365e959",
      "text": "first considering whether any advice or recommendation in this report is suitable for the recipient based on the recipient's particular circumstances and, if appropriate or otherwise needed, seeking professional advice, including tax advice. Jefferies does not perform any suitability or other analysis to check whether an investment decision made by the recipient based on this report is consistent with a recipient's investment objectives, portfolio holdings, strategy, financial situation, or needs.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "b77403d0e069ffc7",
      "text": "By providing this report, neither JRS nor any other Jefferies entity accepts any authority, discretion, or control over the management of the recipient's assets. Any action taken by the recipient of this report, based on the information in the report, is at the recipient's sole judgment and risk. The recipient must perform his or her own independent review of any prospective investment. If the recipient uses the services of Jefferies LLC (or other affiliated broker- dealers), in connection with a purchase or sale of a security that is a subject of these materials, such broker- dealer may act as principal for its own accounts or as agent for another person. Only JRS is registered with the SEC as an investment adviser; and therefore neither Jefferies LLC nor any other Jefferies affiliate has any fiduciary duty in connection with distribution of these reports.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "5501b69edda4ae13",
      "text": "The price and value of the investments referred to herein and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "8ab116e42d8932c2",
      "text": "This report may contain forward looking statements that may be affected by inaccurate assumptions or by known or unknown risks, uncertainties, and other important factors. As a result, the actual results, events, performance or achievements of the financial product may be materially different from those expressed or implied in such statements.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "f3a53ee45509d862",
      "text": "This report has been prepared independently of any issuer of securities mentioned herein and not as agent of any issuer of securities. No Equity Research personnel have authority whatsoever to make any representations or warranty on behalf of the issuer(s). Any comments or statements made herein are those of the Jefferies entity producing this report and may differ from the views of other Jefferies entities.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "28ccdaa1946441cf",
      "text": "This report may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's, and information derived from third- party or proprietary generative artificial intelligence (Gen AI) models. Jefferies does not guarantee the accuracy, completeness, timeliness or availability of this information, and is not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Neither Jefferies nor any third- party content providers, including providers of Gen AI models, give any express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Neither Jefferies nor any third- party content provider shall be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs,",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "529146ba0e375740",
      "text": "expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase, hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "d6fbc54e0c0d6acd",
      "text": "Jefferies research reports are disseminated and available electronically, and, in some cases, also in printed form. Electronic research is simultaneously made available to all clients. This report or any portion hereof may not be copied, reprinted, sold, or redistributed or disclosed by the recipient or any third party, by content scraping or extraction, automated processing, or any other form or means, without the prior written consent of Jefferies. Any unauthorized use is prohibited. Neither Jefferies nor any of its respective directors, officers or employees, is responsible for guaranteeing the financial success of any investment, or accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this report or its contents. Nothing herein shall be construed to waive any liability Jefferies has under applicable U.S. federal or state securities laws.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "236f94f0376a95c4",
      "text": "For Important Disclosure information relating to JRS, please see https://adviserinfo.sec.gov/lAPD/Content/Common/crd_iapd_Brochure.aspx? BRCHR_VRSN_ID=483878 and https://adviserinfo.sec.gov/Firm/292142 or visit our website at https://javatar.bluematrix.com/sellside/Disclosures.action, or www.jefferies.com, or call 1.888. JEFFERIES. Â© 2025 Jefferies",
      "page": 12,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "146914ba3f2b493a",
      "name": "Australian Healthcare",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "091ea27f0512d847",
      "name": "Base Case",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "90a0c1cb6b7a436e",
      "name": "Beach Boys",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "96d7ef641e07c504",
      "name": "Biotechnology Clarity",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "582a2d84addf2c93",
      "name": "Brian Wilson",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "9aaae40855c09cb1",
      "name": "CUV Income",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "35f922c52a7d27a2",
      "name": "Ca Diagnostic",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7860a2554c61a53f",
      "name": "Canadian Investment",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "235d4d014c47f6cf",
      "name": "Clarity\n\nClarityClarity",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "461545c130d3049d",
      "name": "Clarity\n\nClarityClarity Pharmaceuticals Ltd",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "47545e1607138a85",
      "name": "Clarity\n\nIn",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6de4a7934b652d8e",
      "name": "Clarity Pharma",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a99485bb3efae0e9",
      "name": "Clarity Pharmaceuticals",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "5eb19fedb3e1fce8",
      "name": "Clarity Pharmaceuticals Ltd",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6e4788dbad025b7b",
      "name": "Company Description",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a92ba89b9eff6c1b",
      "name": "Company Target",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8bb7d9a681cb9e40",
      "name": "Company Valuation",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4b9be408e155a05b",
      "name": "Coverage Suspended",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e9cd18ef1469e32c",
      "name": "DFSA Reference",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6ba4b0a762d135f4",
      "name": "Dealers Association",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "bar",
        "title": null,
        "page": 1,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2028E",
              "2029E",
              "2030E",
              "2031E",
              "2032E"
            ]
          },
          "y": {
            "unit": "A$m",
            "range": {
              "min": 0,
              "max": 2000
            }
          }
        },
        "series": [
          {
            "name": "Neuroblastoma Diagnostic",
            "unit": "A$m",
            "values": [
              10,
              20,
              30,
              40,
              50
            ]
          },
          {
            "name": "64Cu SAR-bisPSMA (BCR)",
            "unit": "A$m",
            "values": [
              50,
              80,
              120,
              200,
              300
            ]
          },
          {
            "name": "NeuroEndo Ca Diagnostic",
            "unit": "A$m",
            "values": [
              5,
              10,
              15,
              20,
              25
            ]
          },
          {
            "name": "Neuroblastoma Therapeutic",
            "unit": "A$m",
            "values": [
              0,
              0,
              0,
              50,
              70
            ]
          },
          {
            "name": "67Cu SAR-bisPSMA",
            "unit": "A$m",
            "values": [
              0,
              0,
              0,
              300,
              800
            ]
          },
          {
            "name": "PSMA neg. Prost. Ca Diagnostic",
            "unit": "A$m",
            "values": [
              0,
              0,
              0,
              10,
              20
            ]
          }
        ],
        "figure_id": "fb34a138c5799d27",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "table",
        "title": null,
        "page": 1,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "PREV"
            ]
          },
          "y": {
            "unit": null,
            "range": null
          }
        },
        "series": [
          {
            "name": "Values",
            "unit": null,
            "values": [
              -0.07,
              -0.09,
              -0.16
            ]
          }
        ],
        "figure_id": "095a01a33e78e45a",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "line",
        "title": "Rating and Price Target History for: Clarity Pharmaceuticals Ltd (CU6 AU) as of 08-28-2025",
        "page": 9,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 10
            }
          }
        },
        "series": [
          {
            "name": "Price",
            "unit": null,
            "values": [
              0.5,
              0.5,
              0.7,
              0.8,
              1.0,
              1.5,
              2.5,
              4.0,
              8.0,
              4.0,
              3.0,
              4.0
            ]
          },
          {
            "name": "Price Target",
            "unit": "AUD",
            "values": [
              {
                "date": "01/24/2023",
                "value": 2.5
              },
              {
                "date": "08/24/2023",
                "value": 2.6
              },
              {
                "date": "11/30/2023",
                "value": 3.15
              },
              {
                "date": "01/11/2024",
                "value": 3.35
              },
              {
                "date": "03/01/2024",
                "value": 3.45
              },
              {
                "date": "03/26/2024",
                "value": 3.1
              },
              {
                "date": "07/11/2024",
                "value": 6.1
              },
              {
                "date": "07/16/2024",
                "value": 7.4
              },
              {
                "date": "08/23/2024",
                "value": 8.2
              },
              {
                "date": "03/03/2025",
                "value": 7.0
              },
              {
                "date": "04/17/2025",
                "value": 4.7
              },
              {
                "date": "07/17/2025",
                "value": 5.5
              },
              {
                "date": "07/28/2025",
                "value": 5.0
              }
            ]
          }
        ],
        "figure_id": "d5f622a1661f518d",
        "provenance": {
          "page": 9
        }
      },
      {
        "type": "other",
        "title": null,
        "page": 1,
        "axes": null,
        "series": [],
        "figure_id": "9e90f9b7d9eedbe5",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "pie",
        "title": "Evaluation of portfolio",
        "page": 1,
        "axes": {},
        "series": [
          {
            "name": "67Cu SAR-biPSMA",
            "unit": "%",
            "values": [
              54
            ]
          },
          {
            "name": "NeuroEndo Ca Diagnostic",
            "unit": "%",
            "values": [
              2
            ]
          },
          {
            "name": "PSMA neg Prost. Ca Diagnostic",
            "unit": "%",
            "values": [
              1.7
            ]
          },
          {
            "name": "64Cu SAR-biPSMA (BCR)",
            "unit": "%",
            "values": [
              42.4
            ]
          }
        ],
        "figure_id": "2c90c734e0b3b192",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 2,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2024",
              "2025",
              "+12 mo."
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 18
            }
          }
        },
        "series": [
          {
            "name": "Historical/Projected Value",
            "unit": null,
            "values": [
              {
                "x": "2024",
                "y": [
                  1.0,
                  8.5
                ]
              },
              {
                "x": "2025",
                "y": [
                  1.5,
                  4.5
                ]
              },
              {
                "x": "current",
                "y": 3.25
              },
              {
                "x": "+12 mo. (Upside)",
                "y": 16.48
              },
              {
                "x": "+12 mo. (Mid)",
                "y": 5.0
              },
              {
                "x": "+12 mo. (Downside)",
                "y": 0.03
              }
            ]
          }
        ],
        "figure_id": "1a82ef3917595216",
        "provenance": {
          "page": 2
        }
      },
      {
        "type": "bar",
        "title": null,
        "page": 4,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2028E",
              "2029E",
              "2030E",
              "2031E",
              "2032E"
            ]
          },
          "y": {
            "unit": "A$m",
            "range": {
              "min": 0,
              "max": 2000
            }
          }
        },
        "series": [
          {
            "name": "Neuroblastoma Diagnostic",
            "unit": "A$m",
            "values": [
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "64Cu SAR-bisPSMA (BCR)",
            "unit": "A$m",
            "values": [
              30,
              100,
              200,
              250,
              300
            ]
          },
          {
            "name": "NeuroEndo Ca Diagnostic",
            "unit": "A$m",
            "values": [
              0,
              10,
              20,
              30,
              40
            ]
          },
          {
            "name": "Neuroblastoma Therapeutic",
            "unit": "A$m",
            "values": [
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "67Cu SAR-bisPSMA",
            "unit": "A$m",
            "values": [
              0,
              0,
              0,
              400,
              800
            ]
          },
          {
            "name": "PSMA neg. Prost. Ca Diagnostic",
            "unit": "A$m",
            "values": [
              0,
              0,
              0,
              20,
              30
            ]
          }
        ],
        "figure_id": "16c1d4358e1707d8",
        "provenance": {
          "page": 4
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "47c3d0e98e56f0a0",
        "value": 0.57,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Y</td></tr><tr><td>PRICE</td><td>AUD3.18*</td></tr><tr><td>PRICE TARGET | % TO PT</td><td>AUD5.00 | +57%</td></tr><tr><td>52W HIGH-LOW</td><td>AUD8.98 - AUD1.43</td></tr><tr><td>FLOAT (%) | ADV MM (US",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "f4b6ab5141864573",
        "value": 0.667,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>52W HIGH-LOW</td><td>AUD8.98 - AUD1.43</td></tr><tr><td>FLOAT (%) | ADV MM (USD)</td><td>66.7% | 12.91</td></tr><tr><td>MARKET CAP</td><td>AUD1.1B | $700.9M</td></tr><tr><td>TICKER</td><td>",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "e79be26bfa75970c",
        "value": 0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td></tr><tr><td></td><td>2026</td><td>2027</td><td>2026</td><td>2027</td></tr><tr><td>REV</td><td>+22%</td><td>+22%</td><td>NA</td><td>NA</td></tr><tr><td>EPS</td><td>-19%</td><td>-22%</td><td>NA</t",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "6f989b3be18716a0",
        "value": 0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td></td><td>2026</td><td>2027</td><td>2026</td><td>2027</td></tr><tr><td>REV</td><td>+22%</td><td>+22%</td><td>NA</td><td>NA</td></tr><tr><td>EPS</td><td>-19%</td><td>-22%</td><td>NA</td><td>NA</td>",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "55a1563506e26fc2",
        "value": -0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "7</td></tr><tr><td>REV</td><td>+22%</td><td>+22%</td><td>NA</td><td>NA</td></tr><tr><td>EPS</td><td>-19%</td><td>-22%</td><td>NA</td><td>NA</td></tr></table> ![Figure 0-2](images/0_2.jpg) ![Figure 0-3",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "354a4218bba42507",
        "value": -0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><td>REV</td><td>+22%</td><td>+22%</td><td>NA</td><td>NA</td></tr><tr><td>EPS</td><td>-19%</td><td>-22%</td><td>NA</td><td>NA</td></tr></table> ![Figure 0-2](images/0_2.jpg) ![Figure 0-3](images/0_3.",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "68538f0aed88ab7e",
        "value": 203.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "mpared to our forecasts, CU6 had higher R&D and employment expenses. Clarity recently completed a A\\$203m placement. Funds will be used for: 1) clinical development; 2) pipeline advancements; and 3) m",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "943504c8a480b4ed",
        "value": 5.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "and 2) updated for net interest for FY26E+. We make no changes to our CU6 revenue forecasts. PT A\\$5.00 (unchanged). We use the NPV of CU6's late- stage pipeline as our price target. ![Figure 0-1](ima",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "b3f8517026d20a91",
        "value": 700900000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "tr><td>FLOAT (%) | ADV MM (USD)</td><td>66.7% | 12.91</td></tr><tr><td>MARKET CAP</td><td>AUD1.1B | $700.9M</td></tr><tr><td>TICKER</td><td>CU6 AU</td></tr></table> \\\\*Prior trading day's closing pric",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "b57591ab6287bf18",
        "value": 0.57,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "te. ![Figure 1-0](images/1_0.jpg) <center>Risk/Reward - 12 Month View </center> Base Case, AUD5, +57% Our base case price target uses our risk- weighted valuations for the near- term products in the C",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "6f3f476dee41f8e8",
        "value": 4.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "f PSMA+ve prostate cancer and 4) Diagnosis of PSMA -ve prostate cancer. Upside Scenario, AUD16.48, +418% Our upside case price target is a non- risk- weighted valuation of CU6's base- case opportuniti",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "71cfb62b2dca5ef5",
        "value": 0.99,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "s a non- risk- weighted valuation of CU6's base- case opportunities. Downside Scenario, AUD0.03, - 99% Our downside case assumes all clinical trials fail. In this case, the stock would likely trade at",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "fe8675ce21763b59",
        "value": -0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ": No. of men in the US who had radical prostatectomy</td><td>68.5</td></tr><tr><td>BCR occurs in c20-40% of men after radical prostatectomy, assume 30%</td><td>20.5</td></tr><tr><td>CY24E: With BCR po",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "e0996e2e8cc54862",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tomy</td><td>68.5</td></tr><tr><td>BCR occurs in c20-40% of men after radical prostatectomy, assume 30%</td><td>20.5</td></tr><tr><td>CY24E: With BCR postradical prostatectomy, c70% present with a PSA",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "ae595813d98b9e64",
        "value": 0.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "prostatectomy, assume 30%</td><td>20.5</td></tr><tr><td>CY24E: With BCR postradical prostatectomy, c70% present with a PSA &amp;lt;0.75 ng/mL</td><td>14.4</td></tr><tr><td>Assume 2% growth in market C",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "d6f0fbd3ecb33624",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ical prostatectomy, c70% present with a PSA &amp;lt;0.75 ng/mL</td><td>14.4</td></tr><tr><td>Assume 2% growth in market CY24 to CY28E, no. of CY28E scans based on above</td><td>15.6</td></tr></table> ",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "b8de0a3f7bc3b55b",
        "value": 0.42,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ed valuation</td></tr><tr><td>64Cu SAR-bisPSMA (BCR)</td><td>2.10</td><td>61.2</td><td>3.43</td><td>42%</td></tr><tr><td>67Cu SAR-bisPSMA</td><td>2.68</td><td>21.4</td><td>12.50</td><td>54%</td></tr><",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "2df8d9eda3228e24",
        "value": 0.54,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">3.43</td><td>42%</td></tr><tr><td>67Cu SAR-bisPSMA</td><td>2.68</td><td>21.4</td><td>12.50</td><td>54%</td></tr><tr><td>NeuroEndo Ca Diagnostic</td><td>0.10</td><td>61.2</td><td>0.16</td><td>2%</td><",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "ad69fc7831135e13",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>54%</td></tr><tr><td>NeuroEndo Ca Diagnostic</td><td>0.10</td><td>61.2</td><td>0.16</td><td>2%</td></tr><tr><td>PSMA neg. Prost. Ca Diagnostic</td><td>0.08</td><td>21.4</td><td>0.39</td><td>2%",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "d671ac64a9c72f68",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>2%</td></tr><tr><td>PSMA neg. Prost. Ca Diagnostic</td><td>0.08</td><td>21.4</td><td>0.39</td><td>2%</td></tr><tr><td>Total valuation (A$, rounded)</td><td>5.00</td><td></td><td></td><td></td></tr><",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "7a02541d09207f0c",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "y price consistently below \\(10, the expected total return (price appreciation plus yield) is minus 20% or less within a 12- month period. NR - The investment rating and price target have been tempora",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "32f70517465d52ff",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "c4ee129eaaa26bd1",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not ",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "47a239dcd59f3042",
        "value": 0.6063000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>Count</td><td>Percent</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2111</td><td>60.63%</td><td>370</td><td>17.53%</td><td>118</td><td>5.59%</td></tr><tr><td>HOLD</td><td>1213</td><",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "7c6bfe99d3ade70a",
        "value": 0.1753,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2111</td><td>60.63%</td><td>370</td><td>17.53%</td><td>118</td><td>5.59%</td></tr><tr><td>HOLD</td><td>1213</td><td>34.84%</td><td>105</td><",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "cb027ab7425b2ec6",
        "value": 0.0559,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ent</td></tr><tr><td>BUY</td><td>2111</td><td>60.63%</td><td>370</td><td>17.53%</td><td>118</td><td>5.59%</td></tr><tr><td>HOLD</td><td>1213</td><td>34.84%</td><td>105</td><td>8.66%</td><td>22</td><td",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "99ae6138d82c7988",
        "value": 0.34840000000000004,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "63%</td><td>370</td><td>17.53%</td><td>118</td><td>5.59%</td></tr><tr><td>HOLD</td><td>1213</td><td>34.84%</td><td>105</td><td>8.66%</td><td>22</td><td>1.81%</td></tr><tr><td>UNDERPERFORM</td><td>158<",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "ce43e4f644db00c0",
        "value": 0.0866,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "53%</td><td>118</td><td>5.59%</td></tr><tr><td>HOLD</td><td>1213</td><td>34.84%</td><td>105</td><td>8.66%</td><td>22</td><td>1.81%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "f48e49949c524ea0",
        "value": 0.0181,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".59%</td></tr><tr><td>HOLD</td><td>1213</td><td>34.84%</td><td>105</td><td>8.66%</td><td>22</td><td>1.81%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td>",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "66ef6bcfe2f873ba",
        "value": 0.0454,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>105</td><td>8.66%</td><td>22</td><td>1.81%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td><td>1.90%</td></tr></table><ï½endâofâsentenceï½>",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "9dfe8b9d33c68171",
        "value": 0.019,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>22</td><td>1.81%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td><td>1.90%</td></tr></table><ï½endâofâsentenceï½>",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "ea753e1b8089d8e2",
        "value": 0.019,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td><td>1.90%</td></tr></table><ï½endâofâsentenceï½>",
        "provenance": {
          "page": 9
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 7,
      "tables_count": 0,
      "numerical_data_count": 32,
      "passages_count": 112,
      "entities_count": 20
    }
  }
}